Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3937144 | 0.83 | HTT (0.45) | HTTALDH1A1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL3943320 | 0.82 | HTT (0.33) | HTTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3936795 | 0.81 | ALDH1A1 (0.36) | HTTALDH1A1KDM4EHSD17B10RAB9A | |
| SCHEMBL3947587 | 0.80 | MAPK14 (0.33) | — | |
| SCHEMBL3935854 | 0.80 | ALDH1A1 (0.34) | ALDH1A1KDM4E | |
| SCHEMBL3946011 | 0.80 | MAPK1 (0.35) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3946110 | 0.79 | LRRK2 (0.31) | HTT | |
| SCHEMBL3941215 | 0.77 | ADORA1 (0.34) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3944968 | 0.76 | PIK3CD (0.30) | — | |
| SCHEMBL7126242 | 0.75 | HTT (0.34) | HTTALDH1A1KDM4EHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | HTT 3815/4885ALDH1A1 2709/4885KDM4E 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.